GMRx2 ACT1 UK update

We are delighted to initiate our final and 25th GMRx2 Active Control Trial (ACT) site, Belmont Health in Harrow, London. 

Recruitment for the GMRx2 ACT1 study, which is sponsored by George Medicines, is competitive.   

Since the initiation of our first site in Bath in in January 2022, our carefully selected and initiated 24 primary care sites have screened at least 250 patients.

#clinicaltrial #clinicalresearch #imperialcollegelondon #ictuglobal #hypertension #lifesciences #globalhealth #GMRx2 #ARO

For further information regarding our services and how we can collaborate, please contact our team